Increased accuracy in heparin and protamine administration decreases bleeding: a pilot study.

Area of Science:

• Cardiovascular Surgery
• Anesthesiology
• Hematology

Background:

• Postoperative bleeding is a significant complication in cardiac surgery, often necessitating reoperation.
• Heparin/protamine mismatch, including insufficient heparin reversal or protamine overdosing, can cause bleeding when surgical causes are excluded.
• Optimizing anticoagulation management is crucial for patient safety and outcomes in cardiac procedures.

Purpose of the Study:

• To evaluate the efficacy of the Hemochron RxDx heparin-protamine titration system in reducing postoperative bleeding and blood transfusion requirements.
• To assess the system's impact on heparin and protamine dosage during cardiac surgery.

Main Methods:

• Prospective study of 53 cardiac surgery patients over 6 months.
• Test group (n=28) used Hemochron RxDx for heparin and protamine dosing based on activated clotting time (ACT) and heparin response tests.
• Control group (n=25) received weight-based heparin and standard protamine reversal.

Main Results:

• The Hemochron RxDx group showed significantly lower postoperative bleeding (375 mL vs. 600 mL, p = .018).
• Reduced need for blood transfusions was observed in the RxDx group (19% vs. 38%, p = .13), though not statistically significant.
• Significant reductions in initial heparin (p = .04), additional heparin during cardiopulmonary bypass (p = .04), and initial protamine doses (p = .0001) were noted in the RxDx group.

Conclusions:

• The Hemochron RxDx system effectively reduces postoperative blood loss in cardiac surgery.
• Individualized anticoagulation management using dose/response curves based on in vitro analysis appears to minimize bleeding.
• The system allows for significant reductions in heparin and protamine usage, improving safety and potentially reducing costs.